We are delighted to announce our Spring Ethics & GCP Forum Friday 31st March 2023, at the Cruciform Building, University College London.
The agenda is available on our website but is subject to ch…
There has been significant progress in decentralised and hybrid clinical trials in the last few y…
AstraZeneca’s latest DTC spot “We Are Targets” for its chronic kidney disease (CKD) med Farxiga is aimed squarely at the nine in 10 adults who have CKD but are unaware of it.
Treatment involves adult patients with relapsed or refractory diffuse large B-cell lymphoma
Gilead Sciences has announced that the National Institute for Health and Care Excellence (NICE) has recommen…
Citing the “trust gap” as one of the greatest challenges in global health today, Sanofi announced its new NextGen Scholarship program, a global initiative aimed at getting more people from underrepres…
Treatment is a maintenance therapy for certain patients with acute myeloid leukaemia
Ipsen, which is “not at all afraid" to challenge Big Pharma, according to CEO David Loew, is touting a win for its oncology pipeline.
The biotechnology industry begins 2023 at a crossroads.
In many ways, the sector is coming off of one of its toughest years in recent memory. Initial public offerings ground to a halt. A widely follow…
The FDA is making some changes in the accelerated approval process. In this episode, we’ll discuss the recent changes with the FDA’s regulation of cancer drugs and how these shifts will impact the bio…
Sometime before the end of March, a person with the inherited blood disease beta thalassemia will receive an infusion containing hundreds of millions of their own stem cells. These cells will have jus…
As the corporate world evolves in the wake of COVID-19, Sanofi has christened an innovative headquarters to help keep pace.
All of our delegates and members who had course places postponed over the last two years due to covid restrictions/illness have now been contacted directly by the Secretariat. If you had a place booke…